DSIP: doses reported in published research

Sources checked 2026-10-07 · 5 cited studies (3 human, 2 animal, 0 cell culture)

DSIP (delta sleep-inducing peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is a nonapeptide first isolated from rabbit blood in the 1970s. Human dose data come from small intravenous studies published in the 1990s.

Human data: small intravenous studies (5-16 participants each) from the early 1990s.

Studies in people (3)

Human 16 adults with chronic insomnia, double-blind, placebo-controlled

Dose as reported: 25 nmol/kg
Route: Intravenous
Frequency / duration: Afternoon before nights 3, 4 and 5 of a 5-night lab study

Source wording: In the afternoon before the 3rd, 4th and 5th night, half of the patients received intravenously 25 nmol/kg body weight DSIP

Bes F, Hofman W, Schuur J et al.. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology 1992. PubMed PMID 1299794 ↗

Human Healthy women (5 plus 3)

Dose as reported: 25 µg/kg
Route: Intravenous infusion over 30 min (or from 21:30 to 22:30 h)
Frequency / duration: Single infusion

Source wording: GH and PRL secretion was studied in five women after DSIP (25 micrograms/kg bw IV over 30 min) In three other women the circadian rhythm of GH and PRL was studied during DSIP (25 micrograms/kg bw from 2130h to 2230h)

Giusti M, Carraro A, Porcella E et al.. Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women. Psychoneuroendocrinology 1993. PubMed PMID 8475226 ↗

Human Healthy young men (5 per condition; 10 in a second experiment)

Dose as reported: 3 mg or 4 mg total
Route: Intravenous infusion
Frequency / duration: Single infusion from 30 min before to 90 min after a CRH test

Source wording: DSIP (total doses of 3 and 4 mg, respectively, vs. was infused intravenously between 30 min prior to and 90 min after CRH injections DSIP (4 mg, also administered as intravenous infusion)

Späth-Schwalbe E, Schäfer A, Uthgenannt D et al.. Delta-sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion. Psychoneuroendocrinology 1995. PubMed PMID 7777652 ↗

Animal studies (2)

Animal doses are listed exactly as the studies report them. They are not converted to human amounts here; doses do not translate between species by body weight.

Animal Sprague-Dawley rats (focal stroke model)

Dose as reported: 120 µg/kg
Route: Intranasal
Frequency / duration: 60 min before occlusion and for 7 days after (8 days)

Source wording: DSIP or vehicle was applied nasally 60 (±15) minutes prior to the occlusion and for 7 days after reperfusion at dose 120 µg/kg. in the course of 8 days

Tukhovskaya EA, Ismailova AM, Shaykhutdinova ER et al.. Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke. Molecules 2021. PubMed PMID 34500605 ↗

Animal Rats (sleep recording)

Dose as reported: 7 nmol/kg
Route: Intracerebroventricular
Frequency / duration: Single dose at dark onset

Source wording: were injected ICV (7 nmol/kg) into rats at dark onset

Obál F, Kovalzon VM, Kalikhevich VN et al.. Structure-activity relationship in the effects of delta-sleep-inducing peptide (DSIP) on rat sleep. Pharmacol Biochem Behav 1986. PubMed PMID 3754970 ↗

Half-life

No half-life value was found in the sources reviewed for this page.

About this page

Every figure above is copied from the cited source; the source wording is shown with each entry. Where a source does not state something, the page says so.
Only abstracts, open-access full texts, registry records and FDA labels were used, so details found only in a paywalled full text may be missing.
This page does not convert doses between species or into other measures, and gives no preparation or handling information.